Webinar: HCV Treatment in 2016: Genotypes 1, 2, and 3
![slide01 HCV Treatment in 2016: Genotypes 1, 2, and 3](https://www.seaetc.com/wp-content/uploads/2016/10/Slide01-1.jpg)
Facilitated by Cody Chastain, MD
Assistant Professor, Viral Hepatitis Program
Vanderbilt University School of Medicine, Division of Infectious Diseases
October 12, 2016
Other Trainings
Objectives
- List available HCV direct acting antivirals (DAAs) available for HCV therapy in 2016
- Describe appropriate HCV DAA therapies for HCV genotypes 1, 2, and 3
- Evaluate the potential for DAA drug-drug interactions, particularly with HIV antiretroviral therapy.
Presentation
Slides
![slide01 HCV Treatment in 2016: Genotypes 1, 2, and 3](https://www.seaetc.com/wp-content/uploads/2016/10/Slide01-1.jpg)
Facilitated by Cody Chastain, MD
Assistant Professor, Viral Hepatitis Program
Vanderbilt University School of Medicine, Division of Infectious Diseases
October 12, 2016
Objectives
- List available HCV direct acting antivirals (DAAs) available for HCV therapy in 2016
- Describe appropriate HCV DAA therapies for HCV genotypes 1, 2, and 3
- Evaluate the potential for DAA drug-drug interactions, particularly with HIV antiretroviral therapy.
Presentation
Slides
Other Trainings
![slide01 HCV Treatment in 2016: Genotypes 1, 2, and 3](https://www.seaetc.com/wp-content/uploads/2016/10/Slide01-1.jpg)
Facilitated by Cody Chastain, MD
Assistant Professor, Viral Hepatitis Program
Vanderbilt University School of Medicine, Division of Infectious Diseases
October 12, 2016
Objectives
- List available HCV direct acting antivirals (DAAs) available for HCV therapy in 2016
- Describe appropriate HCV DAA therapies for HCV genotypes 1, 2, and 3
- Evaluate the potential for DAA drug-drug interactions, particularly with HIV antiretroviral therapy.